Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23564994 | 1.00 | HPGD (0.65) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5191019 | 0.85 | HPGD (0.63) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13645937 | 0.82 | HPGD (0.67) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL19889050 | 0.78 | HPGD (0.61) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL23122211 | 0.78 | HTT (0.61) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL18793730 | 0.77 | HPGD (0.57) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL17481919 | 0.77 | HPGD (0.55) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL28903374 | 0.75 | HPGD (0.58) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL10823822 | 0.75 | KMT2A (0.52) | HPGDPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL6983416 | 0.75 | HPGD (0.57) | HPGDPOLBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | HPGD 3815/4885POLB 2880/4885KMT2A 3168/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | HPGD 4624/4885POLB 3939/4885KMT2A 501/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | HPGD 3815/4885POLB 2880/4885KMT2A 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.